Skip to main content

Table 3 Factors associated with clinical events

From: Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy

Characteristics

Event 1: change of schedule

Event 2: change in therapy

All grades

Hazard ratio

95% CI

P

Hazard ratio

95% CI

P

Univariate analyses

 Age

  ≤64 vs. ≥65

1.08

0.66–1.73

0.77

0.66

0.39–1.13

0.13

 Sex

  Male vs. female

1.71

0.99–2.96

>0.05

3.07

1.70–5.52

<0.001

 Consulter

  Patients vs. caregiver

0.47

0.22–1.01

>0.05

0.38

0.17–0.84

<0.05

 Cancer type

  Breast cancer

0.85

0.54–1.33

0.47

0.55

0.32–0.93

0.03

  Pancreatic cancer

1.44

0.76–2.73

0.27

2.14

1.08–4.23

0.03

  Ovarian cancer

0.84

0.36–1.97

0.69

0.63

0.21–1.88

0.41

  Colorectal cancer

0.56

0.22–1.41

0.22

0.84

0.31–2.29

0.73

  Soft tissue sarcoma

1.87

0.61–5.70

0.27

1.18

0.32–4.42

0.80

  Gastric cancer

0.91

0.23–3.59

0.89

2.71

0.74–9.87

0.13

  Biliary tract cancer

1.28

0.30–5.47

0.74

1.31

0.26–6.65

0.74

  Liver cancer

0.85

0.16–4.44

0.85

3.02

0.66–13.83

0.15

  Malignant lymphoma

4.34

0.79–24.27

0.09

0.78

0.09–6.78

0.82

  Primary unknown cancer

0.53

0.06–4.78

0.57

0.98

0.11–8.89

0.98

  Endometrial cancer

1.43

0.24–8.67

0.70

2.66

0.44–16.22

0.29

 Objective of therapy

  Adjuvant chemotherapy

0.70

0.51–0.95

<0.05

0.45

0.31–0.65

<0.001

  Palliative chemotherapy

1.05

0.84–1.33

0.65

1.57

1.20–2.05

0.001

  Chemotherapy for blood malignancy

0.23

0.04–1.27

0.09

1.28

0.14–11.16

0.82

Grading of adverse event

  Grade 2 + grade 3 vs. grade 1

6.70

4.06–11.05

<0.001

6.55

3.67–11.67

<0.001

  Grade 3 vs. grade 1 + grade 2

0.38

0.18–0.78

<0.01

0.33

0.15–0.70

<0.01

Multivariate analyses

 Sex

  Male vs. female

   

2.70

1.15–6.30

0.02

 Consulter

  Patients vs. caregiver

   

1.65

0.67–4.06

0.28

 Cancer type

  Breast cancer

   

0.80

0.36–1.77

0.58

  Pancreatic cancer

   

0.58

0.21–1.31

0.17

 Objective of therapy

  Adjuvant chemotherapy

0.96

0.69–1.33

0.78

0.77

0.52–1.15

0.20

 Grading of adverse event

  Grade 2 + grade 3 vs. grade 1

6.58

3.93–11.02

<0.001

6.25

3.31–11.80

<0.001

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us